Mitochondria in human cancer cells have been implicated in cancer cell proliferation, invasion, metastasis and even drug resistance mechanisms, making them a potential target organelle for the treatment of human malignancies. Gentamicin (GM), an aminoglycoside drug, is a small molecule that functions as an antibiotic and has ototoxic and nephrotoxic characteristics. Thus, the delivery of GM to mitochondria in cancer cells would be an innovative anticancer therapeutic strategy. In this study, we attempted mitochondrial delivery of GM in HeLa cells derived from a human cervical cancer. For the mitochondrial delivery, we used MITO-Porter, a liposomal nanocarrier for mitochondrial delivery via membrane fusion. We first encapsulated GM in the aqueous phase of the carrier to construct GM-MITO-Porter. Flow cytometry analysis and fluorescent microscopy observations permitted us to confirm that the GM-MITO-Porter was efficiently taken up by HeLa cells and accumulated in mitochondria, while naked GM was not taken up by the cells. Moreover, cell viability assays using HeLa cells showed that the GM-MITO-Porter induced strong cytotoxic effects related to mitochondrial disorder. This finding is the first report of the mitochondrial delivery of an aminoglycoside drug to cancer cells for cancer therapeutic strategy. 
Introduction
Waksman discovered streptomycin from Streptomyces spp. in 1944 1 , and such aminoglycoside drugs (AGs) are now clinically used in treating infections caused by gram-negative bacteria with a broad antibiotic spectrum all over the world. Some AGs, for example gentamicin (GM), are preferred for use because of their low cost and higher safety by therapeutic drug monitoring, although AGs can cause irreversible hearing loss and renal toxicity caused by mitochondrial damage, the detailed mechanisms responsible for this remain unclear 2 . Mitochondria in the epidermal cells in the organ of Corti or kidneys are vulnerable to AGs 3 , thus the patients with mitochondrial disease have a higher risk for AGs 4 . Actually unexpected adverse effects of AGs have been reported among patients with undiagnosed mitochondrial disease 5 .
On the other hand, mitochondria in human cancer cells are closely related to cancer cell proliferation, invasion, metastasis and even drug resistance mechanisms, because of the power exerted by cancer cells for the production of usable energy [6] [7] [8] . Thus, we hypothesized that the cellular uptake of AGs could kill cancer cells via mitochondrial toxicity, which would lead to an effective strategy for treating cancer in a different way from conventional anticancer agents. It is well known that AGs are efficiently internalized into ear hair cells 3 and kidney distal tubule cells 9 via non-selective cation channels such as the Transient receptor potential vanilloid 4 (TRPV4) 10 , the studies regarding cellular uptake of AGs by cancer cells have not been examined. To date, our knowledge of the anti-tumor effect of AG remains limited, probably because the internalization of AG into cancer cells without specific channels would be difficult. To overcome the first barrier to kill cancer cells via the mitochondrial toxicity of AG, the efficient cellular uptake of AG is required.
We previously developed MITO-Porter, a nanocarrier to deliver nucleic acids, proteins, or certain types of small molecules to mitochondria via membrane fusion [11] [12] [13] [14] . To date, we showed that the MITO-Porter was efficiently taken up by HeLa cells derived from a human cervical cancer, and bio functional cargoes that regulate mitochondrial function were delivered to mitochondria. Here, we validated that the mitochondrial delivery of GM (a model AG) using the MITO-Porter resulted in the killing of HeLa cells via mitochondrial pharmacodynamics (Fig. 1) . Octaarginine (R8) 15, 16 modified on the surface of the MITO-Porter plays important roles in cellular uptake and mitochondrial targeting. It is expected that GM would be delivered to the mitochondrial interior, thus permitting GM to exert a pharmacological effect.
We first prepared a MITO-Porter encapsulating GM conjugated with 7-nitrobenz-2-oxa-1,
3-diazole (NBD) (a fluorescent-dye), GM-MITO-Porter and evaluated its physicochemical
properties including diameters and ζ potentials. We then performed flow cytometry to assess the cellular uptake of the GM-MITO-Porter, and observed the intracellular trafficking of the carrier. We also quantified the mitochondrial targeting rate based on obtained images. Moreover, a comparison of cell toxicity between the GM-MITO-Porter and naked NBD-GM was performed by a cell viability assay. Finally, we validated the correlation between the mitochondrial delivery of NBD-GM and cell toxicity.
Materials and Methods

Materials
Gentamicin Sulfate was purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan) and 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) from Tokyo Chemical Industry Co., Ltd (Tokyo, Japan). The Gentamicin Sulfate was conjugated with NBD-F to synthesize NBD-GM, which was purified as previously reported 17 , and then freeze-dried (see Supplementary materials for the details). In this experiment, NBD-GM was used as a naked GM and packaged in the 
Construction of GM-MITO-Porter
We prepared GM-MITO-Porter by the reverse phase evaporation method 18 . The GM-MITO-Porter contains NBD-GM in the aqueous phase of the carrier. A suspension containing 500 μl of chloroform containing 2.75 μmol lipids [DOPE/SM = 9:2 (molar ratio)], 500 μl of diisopropyl ether and 500 μl of 10 mM HEPES buffer (pH 7.4) including 5 μmol NBD-GM, was prepared in a glass tube. The resulting suspension was sonicated via a small-size digital homogenizer (20KHz; Emerson Electric Co., St Louis, MO) and evaporation of the organic solvent, followed by sonication using a bath-type sonicator (85 W; Aiwa Company, Tokyo, Japan) and mixed with an STR-R8 solution (10mol% of total lipid) to prepare the GM-MITO-Porter. The lipid compositions of the GM-MITO-Porter and control liposomes (GM-R8-EPC-LP, GM-DOPE-LP) are summarized in Table 1 . Unencapsulated NBD-GM was separated by ultracentrifugation (74,000g, 20 min, 4 o C) three times using HIMAC (Hitachi Koki Co., Ltd., Tokyo, Japan). The encapsulation efficiency of the NBD-GM into MITO-Porter was estimated, as described in the Supplementary materials. The diameters and ζ-potentials were measured using Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK), as previously reported 22 .
Evaluation of the cellular uptake of the GM-MITO-Porter by flow cytometry
Cellular uptake of the GM-MITO-Porter was quantified, as previously reported (see the 
Intracellular observation of GM-MITO-Porter using confocal laser scanning microscopy (CLSM)
The intracellular trafficking of carriers was observed using CLSM, as previously reported 
Calculation of mitochondrial targeting rate and mitochondrial occupation rate
We estimated mitochondrial targeting rate and mitochondrial occupation rate of the carriers using Image Pro-Plus software (ver7.0.; Ropper Industries, Sarasota, FL), as described below. Fluorescent images were captured using a FV10i-LIV microscope, as shown in This value indicates the mitochondrial targeting efficiency of the carriers, which is expected to be dependent on the intracellular trafficking of carriers to access mitochondria, not the cellular uptake process. Mitochondrial occupation rate ( Fig. 3C ) was calculated as follows;
Mitochondrial occupation rate (%) = S (yellow) / S (red) × 100
This value was used to evaluate the accumulation of the NBD-GM in mitochondria and is affected by the cellular uptake of the NBD-GM.
Evaluation of Cell Viability
The cell viability was evaluated using WST-1 reagent (Takara BIO Inc., Shiga, Japan), as previously reported (see the reference 22 for the detailed methods). Briefly, HeLa cells (1 × 10 with DMEM containing 10% FBS, under an atmosphere of 5% CO 2 /air at 37 o C for 24 h. The cells were incubated with sample suspensions in 250 μl of serum-free DMEM under an atmosphere of 5% CO 2 /air at 37 o C for 2 h, and the medium was then replaced with DMEM containing serum, followed by incubation for a further 48 h.
The cell viability was measured using a WST-1 Reagent by an EnSpire TM 2300
Multilabel Reader (PerkinElmer, Waltham, MA). The value of cell viability was calculated as follows;
Cell viability (%) = V S /V U × 100, where V S and V U represent the cell viability for treated and untreated cells with samples, respectively.
Statistical analysis
The cellular uptake of NBD-GM by the carriers were evaluated in Fig. 2B , and the statistical significance between the non treatment and others were calculated by one-way ANOVA, followed by the Bonferroni/Dunn test. In Fig. 3B , the mitochondrial targeting rates were evaluated and the statistical significance between the GM-MITO-Porter and GM-R8-EPC-LP were calculated by the student t-test. In Fig. 4A , cellular viabilities were evaluated, and statistical significances were calculated between naked NBD-GM and others by one-way ANOVA, followed by the Bonferroni/Dunn test. In Fig. 4B , the cellular uptake was evaluated and statistical significances between the GM-MITO-Porter and GM-R8-EPC-LP were calculated by the student t-test. Levels of p values < 0.05 were considered to be significant.
Results
Construction of the GM-MITO-Porter
We used NBD-GM for the encapsulation in the MITO-Porter, where the mitochondria-fusogenic lipid composition was used 11, 12 . After the synthesis and purification of the NBD-GM, we performed a competitive enzyme immunoassay to evaluate the antibacterial activity of NBD-GM using a MaxSignal Gentamicin ELISA Test Kit (Bio Scientific Corporation, Austin, TX). The findings showed that the activity of the NBD-GM was 52 ± 19% of the antibacterial activity of the unconjugated GM (n=3).
Using a reverse phase evaporation method, we succeeded in preparing a GM-MITO-Porter in which the nanoparticles were positively charged (147 ± 6 nm, 44 ± 4 mV, n=3) and the encapsulation efficiency of the GM in the MITO-Porter was 6 ± 2% (n=3). Although the encapsulation efficiency appeared to be low, it was within the value expected for encapsulating very hydrophilic and cationic low-weight molecules 20 . We checked the stability of the GM-MITO-Porter, and confirmed that the diameter and ζ-potential were stable in the liquid at 4 o C for one month (Fig.   S1 ). The GM-MITO-Porter was equipped with STR-R8 as a cellular uptake device 15, 16 . In this experiment, we also prepared a GM-R8-EPC-LP with high cellular uptake and low mitochondrial fusion activities and a GM-DOPE-LP with low cellular uptake and mitochondrial fusion activities.
The diameters of the prepared carriers were comparable (approximately 100-200 nm) as shown in Table 1 . The ζ-potentials of the GM-MITO-Porter and the R8-EPC-LP were positively charged, suggesting that the cationic R8 was displayed on the carrier surface.
Evaluation of cellular uptake of GM-MITO-Porter
Although it is well known that GM is efficiently internalized into ear hair cells and kidney distal tubule cells 3, 9 , it has not been demonstrated that GM can be taken up by cancer cells.
Therefore, we first evaluated the cellular uptake of NBD-GM as naked GM using HeLa cells as model cancer cells by flow cytometry (Fig. 2) . The fluorescence intensities of the NBD-GM taken up by the cells were comparable to that of non-treated cells, indicating a low cellular uptake of naked NBD-GM in the case of HeLa cells. Intracellular observations also showed that NBD-GM was not taken up by the HeLa cells (Fig. S2A ). On the other hand, in the case of Pheochromocytoma cell 12
(PC12) cells where TRPV4 was found to be highly expressed 21 , the NBD-GM was efficiently internalized into the cells (Fig. S2B) . We also performed an RT-PCR assay to detect TRPV4-mRNA, resulting in the observation of the gene expression of TRPV4 in the case of PC12 cells, while this was not observed in the case of HeLa cells (Fig. S3) . These results indicate that the first barrier for killing cancer cells via mitochondrial toxicity by mitochondrial delivery of GM is the plasma membrane.
We previously reported that the MITO-Porter, modified with STR-R8, was efficiently internalized into HeLa cells 22, 23 . Based on these reports, we hypothesized that MITO-Porter would likely permit GM to be efficiently internalized into HeLa cells. As shown in Fig. 2A , the fluorescence intensities of the NBD-GM taken up by the cells were relatively high in the case of GM-MITO-Porter and GM-R8-EPC-LP, although the value for the GM-DOPE-LP that was not modified with STR-R8 was comparable to that of naked NBD-GM. As shown in Fig. 2B , both the cellular uptakes of GM-MITO-Porter and GM-R8-EPC-LP were significantly higher than that for GM-DOPE-LP and naked NBD-GM. These results indicate that the R8 modified carriers are able to internalize NBD-GM into HeLa cells. We used the GM-MITO-Porter and GM-R8-EPC-LP in subsequent experiments.
Intracellular observation of GM-MITO-Porter using CLSM
The final process for mitochondrial delivery includes the introduction of the cargos into the mitochondrial compartment. We observed the intracellular trafficking of the GM-MITO-Porter, GM-R8-EPC-LP and NBD-GM in HeLa cells after staining the mitochondria red (Fig. 3A) . When the GM-MITO-Porter was added to HeLa cells, several yellow clusters were observed, indicating that the green labeled GM (NBD-GM) co-localized with the red stained mitochondria. Only little yellow clusters were observed in the case of GM-R8-EPC-LP, which has a low mitochondrial fusion activity.
We quantified the mitochondrial targeting rate based on the obtained images, showing that the value for the GM-MITO-Porter (12±3% (n=32)) was significantly higher than that of GM-R8-EPC-LP (4±1% (n=32)) (Fig. 3B) . Moreover, we calculated the mitochondrial occupation rate (Fig. 3C) , and confirmed that, in mitochondria that contained the GM-MITO-Porter, its content increased with increasing applied dose. At an applied dose of 10 μM NBD-GM, the mitochondrial occupation rate of GM-MITO-Porter was about 2.5%, while the value for GM-R8-EPC-LP was about 1/50 that of the GM-MITO-Porter (0.05 ± 0% (n=30)).
Evaluation of cellular toxicity after mitochondrial delivery of NBD-GM using the MITO-Porter system
Cellular toxicity was evaluated by means of a cell viability assay of HeLa cells after the mitochondrial delivery of NBD-GM by MITO-Porter system. The results showed that cell viability was decreased with increasing applied dose of the GM-MITO-Porter, and the effective concentration 50 (EC 50 ) was 2.2 μM of NBD-GM (circles in Fig. 4A ). Meanwhile, cell viability was not decreased in the case of GM-R8-EPC-LP (squares) or NBD-GM (diamonds) (Fig. 4A) , although the cellular uptake of the GM-R8-EPC-LP were comparable with the GM-MITO-Porter at same applied doses (Fig. 4B) . We also observed no cell toxicity, when the empty MITO-Porter was used (Fig. S4) . We also validated the relationship between cellular toxicity and the mitochondrial accumulation of NBD-GM as shown in Fig. 4C . The results showed that the toxicity steadily increased with the amount of NBD-GM in mitochondria (Fig. 4C ).
Discussion
In previous study, it has been reported that AGs have a high affinity for ribosomal RNA and permeability transition in mitochondria, resulting in apoptosis via the inhibition of mitochondrial transcription or exaggerated oxidative stress, which are consistent with the molecular mechanisms for the ototoxicity and nephrotoxicity induced by AGs [24] [25] [26] . AGs have been clinically available as antibiotics for many years, and, unfortunately, can exert some irreversible adverse-effects, especially in the patients with a mitochondrial disease. AGs are not only antibiotics, but also function as latent mitochondrial toxic agents. In this study, we validated whether AGs would have anticancer activity once they are delivered into mitochondria.
However, this validation would be difficult using naked AGs because they cannot readily penetrate the cellular membrane without selective channels such as TRPV4 9, 21 . As shown in Fig. 3A ,
NBD-GM as a model AG was not internalized into HeLa cells, which do not express high levels of TRPV4. Thus, we designed the GM-MITO-Porter, in which NBD-GM was encapsulated by mitochondrial fusogenic envelopes modified with STR-R8, i.e., a cellular uptake device. We could confirm that the GM-MITO-Porter achieved mitochondrial delivery of NBD-GM in cancer HeLa cells (Figs. 2, 3 ).
The mitochondrial delivery of NBD-GM using the MITO-Porter system resulted in a decreased cell viability and the effect was dose-dependent (Fig.4A) , and the more the mitochondrial accumulation of NBD-GM increased, the lower was the cellular viability (Fig.4C) . Irrespective of the low encapsulation efficiency, the GM-MITO-Porter had significant cellular toxicity; the EC 50 was 2.2 μM of NBD-GM where the total lipid concentration was theoretically only about 6 μM.
Based on this value, the GM-MITO-Porter would be predicted to have a therapeutic effect in the human body as a liposomal drug. Under an ideal scenario, only about 30 μmol of the total amount of lipid would be needed for each drip-in-vein to reach the EC 50 of the blood GM concentration, assuming that the total circulating blood volume is 5 L. On the other hand, Doxil, which is a clinically available liposomal drug encapsulating doxorubicin, requires about 1 mmol of the total lipid amount for each drip-in-vein 27 . The GM-MITO-Porter might have some drug advantages, in that a smaller amount of total lipids is needed for each drip-in-vein.
It was reported that the mitochondrial toxicity of GM in ear hair cells could be induced by the inhibition of mitochondrial transcription by binding to ribosomal RNA 24 or by opening permeability transition pores by induced oxidative stress and metabolic change 25 . Thus, we hypothesized that the delivery of NBD-GM into mitochondria of cancer HeLa cells might lead to cell death via a mechanism similar to that reported for ear hair cells. Attention should be paid to the . These studies are currently under way.
Conclusion
In order to investigate the intracellular dynamics and cellular toxicity of AGs using Schematic image of the mitochondrial delivery of NBD-GM by the MITO-Porter system, leading to mitochondrial toxicity.
Fig. 2
Flow cytometry analysis to evaluate the cellular uptake of the GM-MITO-Porter. The histogram plot
( Fig. 2A) column (4.6 x 250 mm, GL Sciences, Tokyo, Japan) with a 30% acetonitrile water-solution. The HPLC profile was detected at 336 nm. A new peak eluted at 2 -2.5 min, and this peak was collected as the NBD-GM, and was then freeze dried.
2.
Estimation of encapsulation efficiency of the NBD-GM into MITO-Porter.
To estimate the encapsulation efficiency of the NBD-GM, a GM-MITO-Porter Upper panel in Fig. S3 shows that the PCR product derived from rat TRPV-4 (403 bp) was present in PC12 cells (lane 4), while that from human TRPV-4 was not observed in HeLa cells (lane 2). We also confirmed that a band corresponding to human TRPV-4 (352 bp) was observed in HaCaT cell (a human TRPV-4 positive cell). In lower panel in Fig. 3 , the PCR products derived from GAPDH-mRNA (internal control) were observed in all kinds of cells (lanes 2, 4, 6). These results suggest that the gene expression of TRPV4 was observed in the case of PC12 cells, but not in the case of HeLa cells.
Moreover, gel images of RT-PCR detection showed that the target DNA bands disappeared in the absence of reverse transcription (RT(-)) (lanes 3, 5, 7), suggesting that contaminating DNA was not present when this RT-PCR assay was performed. Data are represented by the mean ± S.D. (n = 3). Significant differences were calculated by the student t-test and no significant difference (N.S.) were found. Note: lipid concentration of GM-MITO-Porter at 10 μM NBD-GM as shown in Figure 4A was about 10 μM.
